Jefferies Financial Group started coverage on Merck KGaA shares.

1 report, 1 independent Updated Jun 29

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Merck KGaA Jefferies Financial Group

Keep exploring

Part of

Merck KGaA received analyst coverage and increased institutional stake in its stock from various firms. All 1 developments

The entities involved

Merck KGaA
German multinational science and technology company
- Bioinvent presented data combining its BI-1808 therapy with MSD's KEYTRUDA® at the ESMO Congress in Madrid.Sat 09:06
- Oncolytics Biotech and Merck KGaA signed a co-development agreement for the immunotherapy candidate pelareorep.Sat 01:42
Jefferies Financial Group
American financial services company
- Jefferies Financial Group initiated coverage on Moody's shares, and Morgan Stanley subsequently raised its price target for the company.Sun 08:21
- Analyst firms Jefferies, TD Cowen, and Raymond James Financial provided rating updates for Black Diamond Therapeutics, alongside MarketBeat consensus data.Sun 07:42

Related events

Morgan Stanley reduced its price target on Merck KGaA while Manufacturers Life Insurance Company increased its holdings in the stock.Oct 15
Merck KGaA and ABVC BioPharma are competing for investment as healthcare companies.Oct 16

Coverage

Newest first; wire copies grouped

Jun 29themarketsdaily.com